SYK - Stryker Corporation
| Previous Close | 176.23 |
| Open | 176.42 |
| Bid | 170.62 x 900 |
| Ask | 176.97 x 800 |
| Day's Range | 171.43 - 176.50 |
| 52 Week Range | 146.80 - 179.84 |
| Volume | 1,203,597 |
| Avg. Volume | 1,230,495 |
| Market Cap | 64.738B |
| Beta (3Y Monthly) | 0.26 |
| PE Ratio (TTM) | 61.12 |
| EPS (TTM) | 2.83 |
| Earnings Date | Oct 25, 2018 |
| Forward Dividend & Yield | 1.88 (1.07%) |
| Ex-Dividend Date | 2018-09-27 |
| 1y Target Est | 187.27 |
Market Realist•16 hours agoZimmer Biomet Holdings: Revenue Trends ahead of Its Q3 Earnings
Zimmer Biomet Holdings (ZBH) plans to release its third-quarter earnings on October 26. Wall Street analysts expect ZBH to generate revenues of $1.8 billion in the third quarter.
Market Realist•21 hours agoWhat Analysts Expect for Boston Scientific Stock
Of the total 25 analysts covering Boston Scientific (BSX) in October 2018, 22 analysts have given Boston Scientific a “buy” or higher rating, and three analysts have given Boston Scientific a “hold” rating. The mean rating for Boston Scientific is 1.52 with a target price of $41.57, which implies an upside potential of 9.4% over Boston Scientific’s closing price of $38.0 on October 17, 2018.
Market Realist•21 hours agoWhat Can We Expect from Tandem’s Bottom Line in Third Quarter?
Tandem Diabetes Care (TNDM) is expected to incur a net loss of $18.22 million in the third quarter of 2018. Its net loss was $16.03 million in the year-ago period, which translates into a net loss per share of $0.33 for the third quarter of fiscal 2018 as compared with a net loss per share of $3.09 for the third quarter of fiscal 2017. On October 12, Tandem announced that its t:slim X2 insulin pump received approval in Canada and is the only continuous glucose monitoring (or CGM) integrated insulin pump approved in the country.
- Zacks•21 hours ago
Stryker (SYK) Q3 Earnings Preview: What's in the Cards?
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Market Realist•21 hours agoWhat Will BSX’s Q3 Operational Performance Look Like?
Boston Scientific’s (BSX) gross income is expected to increase by 9.26% from $1.58 billion in the third quarter of fiscal 2017 to $1.73 billion in the third quarter of fiscal 2018. Its gross margin is expected to expand from 71.33% for the third quarter of fiscal 2017 to 71.95% for the third quarter of fiscal 2018.
Market Realist•yesterdayGauging Analysts’ Views on Varian Stock
Three of the nine analysts covering Varian Medical Systems (VAR) in October have given the stock “strong buy” ratings, three have given it “hold” ratings, and three have given it “sell” ratings.
Market Realist•2 days agoWhat to Expect from Varian’s Bottom Line in Q4 2018
Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018 compared to $82.7 million in the fourth quarter of fiscal 2017, a rise of 27.02%. The company’s net income translates to a net income per share of $1.13 in the fourth quarter of fiscal 2018 compared to $0.89 in the fourth quarter of fiscal 2017. Varian Medical Systems generated free cash flow of $340.0 million in fiscal 2017.
Market Realist•2 days agoHow Varian’s Operational Performance Is Expected to Look in Q4
Varian’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 44.23% and 44.15%, respectively. In comparison, the fiscal 2018 gross margins of its peers Globus Medical (GMED), Stryker (SYK), and Zimmer Biomet Holdings (ZBH) are expected to be 77.01%, 66.27%, and 71.91%, respectively. Varian Medical Systems is expected to incur selling, general, and administrative expenses of $140.77 million in the fourth quarter of fiscal 2018 compared to $51.70 million in the fourth quarter of fiscal 2017, a rise of more than 100%.
- GlobeNewswire•4 days ago
MERGER ALERT – EGN, KTWO and RLJE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
NEW YORK, Oct. 15, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
- GlobeNewswire•4 days ago
Analysis: Positioning to Benefit within PTC, H&R Block, GenMark Diagnostics, American International Group, Newmont Mining, and Stryker — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Market Realist•9 days agoHow Intuitive’s Bottom Line Is Expected to Look in Q3 2018
Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% from $227.5 million in the third quarter of 2017 to $265.76 million in the third quarter of 2018. In the third quarter, Intuitive Surgical is expected to incur selling, general, and administrative expenses of $207.11 million compared to $204.8 million in the third quarter of 2017, reflecting a potential increase of 1.13%. Intuitive Surgical is expected to report net income of $258.28 million in the third quarter compared to net income of $297.5 million in the third quarter of 2017, indicating a contraction of 13.18% in the company’s net margins.
Market Realist•9 days agoWhy Most Analysts Are Bullish on Intuitive Surgical in October
Eleven of the 18 analysts covering Intuitive Surgical (ISRG) in October have given the stock “buy” or higher ratings. Six analysts have given it “hold” ratings, and one has given it a “sell” rating.
- Zacks•10 days ago
General Dynamics' Unit Wins Arms Deal for Stryker Vehicles
General Dynamics' (GD) Stryker Family of armored combat vehicles provides the U.S. Army with an effective mix of capabilities, including infantry transport, offensive firepower and reconnaissance
- Zacks•11 days ago
General Dynamics Wins $367M Army Deal for Upgrading Stryker
General Dynamics' (GD) Stryker Land Vehicle assists the U.S. Army with capabilities that include infantry transport, offensive firepower and reconnaissance.
- Zacks•16 days ago
Stryker's HyperBranch Buyout to Boost Neurotechnology Business
Stryker's (SYK) craniomaxillofacial division's market prospects bright.
- The Wall Street Journal•18 days ago
[$$] Stryker Buys HyperBranch for $220 Million
Stryker Corp. on Monday said it acquired venture-backed medical-device maker HyperBranch Medical Technology Inc. in an all-cash deal valued at about $220 million.
Market Realist•21 days agoWhat ResMed’s Valuation Trend Indicates
Ten analysts covered ResMed (RMD) in September. Four analysts gave ResMed stock a “buy” or higher rating, five analysts gave it a “hold” rating, and one analyst gave it a “strong sell” rating. The mean rating for ResMed stock is 2.6, and its target price is $104.69.
Market Realist•21 days agoWhat’s the Upside Potential for Agilent Technologies Stock?
In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018. The enterprise value of Agilent is $22.11 billion, and its enterprise-value-to-revenue ratio is 4.6x. Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 3.6x.
Market Realist•22 days agoAgilent’s Top Line Expected to Stay on Upward Trajectory
Agilent Technologies (A) generated total revenues of $1.2 billion in the third quarter of 2018 compared to $1.11 billion in the third quarter of 2017. Agilent generates revenues from product sales and services. For fiscal 2018 and 2019, Agilent is expected to generate revenues of $4.88 billion and $5.18 billion, respectively, compared to $4.47 billion in fiscal 2017.
Market Realist•22 days agoWhat Waters Corporation’s Valuation Trend Indicates
The mean rating for Waters Corporation stock is 2.8, and its target price is $205.79, implying an upside potential of 5.7% over its closing price of $194.69 on September 26. In comparison, for peers Danaher (DHR), Stryker (SYK), and Thermo Fisher Scientific (TMO), analysts have mean ratings of 1.83, 1.93, and 1.63, respectively, and target prices of $114.07, $184.43, and $252.86, respectively. From its level of $218.70 on January 29, the stock corrected to $186.44 on August 15.
Market Realist•22 days agoHow Waters Corporation Is Positioned in 2018
Waters Corporation (WAT) is a specialty measurement company and a pioneer in analytical workflow solutions that involve liquid chromatography, mass spectrometry, and thermal analysis innovations. Additionally, Waters Corporation’s thermal analysis, rheometry, and calorimetry instruments are used in predicting the stability and suitability of fine chemicals, pharmaceuticals, water, polymers, and viscous liquids. Waters Corporation generated total revenue of $596.22 million in the second quarter compared to $558.25 million in the comparable period of 2017.
- GlobeNewswire•28 days ago
MERGER ALERT – IVTY, EGL and ESND: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
NEW YORK, Sept. 21, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following ...
Market Realist•last monthWhat’s the Upside Potential of Thermo Fisher Scientific Stock?
So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors. Boosted by its strong financial performance, it’s risen from $192.98 on January 2 to its current level of $240 in September.
Market Realist•last monthWhat Thermo Fisher Scientific’s Gross Margin Trend Indicates
Thermo Fisher Scientific (TMO) is a leading provider of analytical instruments, equipment, reagents, and consumables. Thermo Fisher Scientific generated total revenue of $6.08 billion in the second quarter compared to $4.99 billion in the comparable period of 2017. Thermo Fisher generates revenue from product sales and services.
- GlobeNewswire•last month
MERGER ALERT – IVTY and EGL: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
NEW YORK, Sept. 14, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following ...
